Premium
Radio‐guided surgery in neuroendocrine tumors
Author(s) -
Gulec Seza A,
Baum Richard
Publication year - 2007
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20868
Subject(s) - neuroendocrine tumors , somatostatin receptor , octreotide , somatostatin , medicine , scintigraphy , in vivo , receptor , cancer research , nuclear medicine , oncology , biology , microbiology and biotechnology
Abstract The majority of Neuroendocrine tumors (NET) express somatostatin (SS) receptors, and thus can be successfully targeted with radiolabeled SS analogs in vivo. Somatostatin receptor scintigraphy (SRS) with 111 In‐DTPA Octreotide is the main imaging technique for evaluation of NETs. Radio‐guided surgery for NETs, therefore, primarily utilizes 111 In‐DTPA Octreotide tumor localization mechanism and kinetics. Somatostatin analog radiopharmacy continues to evolve to include the development of more selective and higher affinity analogs and PET tracers. These changes are expected to open new venues for radio‐guided surgery technology. J. Surg. Oncol. 2007;96:309–315. © 2007 Wiley‐Liss, Inc.